Lupin is currently trading at Rs. 757.00, up by 9.45 points or 1.26% from its previous closing of Rs. 747.55 on the BSE.
The scrip opened at Rs. 756.90 and has touched a high and low of Rs. 760.85 and Rs. 741.55 respectively. So far 57894 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 986.00 on 10-Sep-2018 and a 52 week low of Rs. 720.40 on 28-Mar-2019.
Last one week high and low of the scrip stood at Rs. 789.00 and Rs. 736.10 respectively. The current market cap of the company is Rs. 34300.63 crore.
The promoters holding in the company stood at 46.97%, while Institutions and Non-Institutions held 38.07% and 14.96% respectively.
Lupin has launched Budesonide Inhalation Suspension, 0.5 mg/2 mL Single-Dose Ampules in the US market, having received an approval from the United States Food and Drug Administration (USFDA) earlier. Budesonide Inhalation Suspension, 0.5 mg/2 mL Single-Dose Ampules had annual sales of approximately $385.4 million in the US (IMS MAT March 2019).
The company’s Budesonide Inhalation Suspension, 0.5 mg/2 mL Single-Dose Ampules is a generic version of AstraZeneca Pharmaceuticals LP’s Pulmicort Respules Inhalation Suspension, 0.5 mg/2 mL. It is indicated for the maintenance treatment of asthma and as prophylactic therapy in children from 12 months to 8 years of age.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.